Hi-Tech Pharmacal (HITK)l’s ECR Pharmaceuticals Subsidiary Launches Hylase® Wound Gel
1/18/2012 6:20:20 AM
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that it has acquired marketing and distribution rights to a topical wound gel product from Glycobiosciences , Inc. The hyaluronic acid and emollient based gel is a proprietary patented device approved by the FDA pursuant to Section 510 (k). The product will be marketed under the brand name Hylase® Wound Gel and is indicated for the management and treatment of leg ulcers, pressure ulcers, diabetic ulcers and exuding wounds prone to bleeding. Hylase® will be promoted to physicians, hospitals and nursing care facilities by ECR Pharmaceuticals, Hi-Tech's branded subsidiary.